Overview

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
0
Participant gender:
All
Summary
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Paragon Biomedical
Treatments:
Etanercept
Criteria
Inclusion Criteria:

- Diagnosis of Psoriasis for 6 MO

- BSA 10%

- PASI 12 or above

- PGA 3 or above

Exclusion Criteria:

- Previous exposure to either etanercept or ABT-874